An interventional study of Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase and Transcutaneous Electrical Nerve Stimulation (TENS) during luteal phase in Primary Dysmenorrhea, sponsored by Naiara Benítez Aramburu. Completed at 1 site in Spain. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Naiara Benítez Aramburu · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Dysmenorrhea with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dysmenorrhea · Spain.
Among the 23 studies in Dysmenorrhea with a site in Spain, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2024, is one of 16 with no phase, and was the 14th registered.
432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.
Browse Dysmenorrhea studies →3 of the 23 studies in Dysmenorrhea with a site in Spain are open now. Recruiting first, the newest first:
University of Alcala · Sites in Spain
Ages 18–40 · Women only
Universidad Rey Juan Carlos · Sites in Spain
Ages 18–45 · Women only
Swiss GO Trial Group · Sites in Spain, Belgium, Poland and 1 more country
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 12 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 5 started in 2024.
This study's enrollment of 60 is close to the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Median enrollment 60 across the 20 interventional studies, 400 across the 3 observational. Of the 18 that completed or were terminated, 3 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 23 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Naiara Benítez Aramburu as lead sponsor.
Naiara Benítez Aramburu has 1 study filed under Dysmenorrhea — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Dysmenorrhea with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The effectiveness of non-invasive neuromodulation in adult women with primary dysmenorrhea, through the TENS stimulation at different times in each group: during the bleeding phase (G1), between days 1 and 3 of menstrual cycle, and in the luteal phase (GI2), between days 17 to 24 of menstrual cycle.
The control group (CG) will be treated just like GI1, during the bleeding phase, but without the TENS transmitting the current. Participants will be evaluated by the NPRS, MPQ, SF12, CVM-22, HADS, PCS, PSQI and UDP in the first day of menstruation. Aditionally, GI1 and GC women, will be evaluated inmediatelly after the first sesion of treatment.
This RCT will evaluate women of legal age, with pain greater than 3 on the NPRS scale, and whose menstrual cycle is regular, considered regular between 25-30 days. The sample will be divided into a cases group, which in turn will be divided into 2 subgroups: stimulation intervention in women with dysmenorrhea during the bleeding phase (GI1), and in the luteal phase (GI2). On the other hand, the control group (CG) will be treated just like GI1, during the bleeding phase, but without the transcutaneous electrical nerve stimulation (TENS) transmitting the current.
Initially, a screening questionnaire will be completed. Subsequently, a first assessment will be done to all included participants, which will be conducted by completing the Numerical Pain Scale (NPRS) in relation to their pain for 7 days, McGill Pain Questionnaire (MPQ), SF12 Health Survey, Specific Quality of life Questionnaire Related to Menstruation (CVM-22), Hospital Anxiety and Depression Scale (HADS) and Pain Catastrophizing Scale (PCS) and Pittsburgh Sleep Quality Index (PSQI), as well as pressure pain threshold measure (PPT).
Participants of G1 and GC group, will contact the researcher again to comunicate again the first day of bleeding of this second cycle to being evaluated that same day (without 24 hours passing). In this case, the scales, questionnaires and PPT are done before the intervention in order to observe possible changes from one cycle to another, so that it can be seen if the improvement achieved after treatment has been due to the treatment or other factors. Once the intervention in the bleeding phase is completed, only pain and PTT will be assessed. A second session will be done after 48 hour, but without any data being collected this time, and repeating the assessment on the first day of bleeding of the third cycle.
Regarding GI2, the two interventions sessions will be executed in the middle of the luteal phase, considering 21 days after the cycle start. They will be evaluated again on the first day of the bleeding of the second cycle, within 24 hours, which is estimated to be 7 days after the intervention.
This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Participants allocated to this arm will receive active TENS during the bleeding phase.
Device: Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase
Participants allocated to this arm will receive active TENS during the luteal phase.
Device: Transcutaneous Electrical Nerve Stimulation (TENS) during luteal phase
Participants allocated to this arm will receive sham TENS during the bleeding phase.
Device: Sham Transcutaneous Electrical Nerve Stimulation (TENS) during bleeding phase
Transcutaneous electrical nerve stimulation will be applied for 30 minutes on the first and third days of menstrual bleeding using a TENS device with 4 electrodes placed bilaterally along the midline of the lumbosacral region.
Transcutaneous electrical nerve stimulation will be applied for 30 minutes on cycle days 21 and 23, corresponding to the mid-luteal phase, using a TENS device with 4 electrodes placed bilaterally along the midline of the lumbosacral region.
The same procedure will be performed during the bleeding phase, but without delivering electrical current.
Pain: Numerical Pain Scale (NPRS)
It evaluates the intensity of menstrual pain in this case. This scale is based on asking the patient about the intensity of their pain between a value of 0, which corresponds to the absence of pain, and a value of 10, which corresponds to the highest possible pain.
Time frame: Pain intensity on the first day of menstrual bleeding will be assessed, in addition to the three days preceding and following it, across three consecutive cycles.
Pressure pain threshold (PDU): Analog pressure algometer (Wagner FPX, United States)
Pressure pain thresholds (PPTs) will be assessed in the abdominal and lumbar regions, corresponding to the usual areas of referred pain in women with dysmenorrhea. Five points will be evaluated in the lower abdominal region: two symmetrically located 4 cm from the umbilicus, two at the midpoint between the umbilicus and the anterior superior iliac spine, and one on the midline above the pubic symphysis (T10-T12). In the posterior region, the PPT will be measured at one point on the midline just below the last lumbar vertebra (L5), another at the central sacral level (S2-S4), and additionally at one point on the lateral wall of the right and left ischiorectal fossa. Bilateral assessments will also be conducted at control sites: the temporal region, the lateral aspect of the arm 10 cm below the lateral border of the acromion (C6-C7), and the anterior aspect of the thigh 15 cm above the superior edge of the patella (L2-L3).
Time frame: Assessments will be conducted on the first day of menstrual bleeding (within 24h) across three consecutive cycles. In the second cycle, both groups will undergo two assessments instead of one, carried out before and after the first treatment session.
Anxiety and Depresion: Hospital Anxiety and Depression Scale (HADS)
It is a 14-item self-administered questionnaire composed of two 7-item subscales: anxiety and depression. Each item is scored from 0 to 3, yielding subscale scores ranging from 0 to 21. Higher scores indicate greater symptom severity and a worse outcome of anxiety or depressive symptoms. The timeframe refers to the previous week.
Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
Catastrophic thinking: Pain Catastrophizing Scale (PCS):
It is a self-report inventory that assesses pain catastrophizing, composed of 13 items, which are grouped into 3 factors, which are cognitive rumination, magnification, and hopelessness. Using a five-point Likert scale (0, not at all; 1, a little; 2, moderately; 3, a lot; and 4, all the time), the informant rates the intensity with which she has experienced each thought while experiencing pain. The higher the score, the greater the pain catastrophizing, which could be a total of 52 points.
Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
Sleep quality: Pittsburgh Sleep Quality Index (PSQI):
It is a self-administered questionnaire that measures sleep quality, in addition to the subject's own perception of their sleep. It consists of 24 questions, of which 19 must be answered by the patient themselves (15 closed questions from 0 to 3, and 4 open), while 5 require feedback from the partner or roommate. The 19 self-assessed items are combined to form 7 scoring components (sleep quality, latency, duration, habitual efficiency, sleep disturbances, taking sleep medications, and daytime disturbances), each with a range of 0 to 3. A score of 0 points indicates that there is no difficulty, while a score of 3 corresponds to severe difficulty. The sum of the 7 components would give the global score, which has a range of 0 to 21 points, indicating severe difficulty in all the areas studied, as the score increase.
Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
Quality of life: SF12 Health Questionnaire
It evaluates multidimensional health and it consists of 12 items (physical function, social function, physical role, emotional role, mental health, vitality, body pain and general health). It is a self-administered questionnaire, where the number of response options ranges between 2 and 6, among which the patient can only choose one. This questionnaire allows to obtain two scores, which correspond to the physical summary and the mental summary. A higher score is related to better health status.
Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
Pain: McGill Pain Index (MPQ)
The McGill Pain Questionnaire (MPQ), developed by Melzack (1975), is a multidimensional tool with 78 descriptors across sensory, affective, evaluative, and miscellaneous dimensions. It characterizes pain quality and intensity through the Pain Rating Index (PRI) (0-78 total), Number of Words Chosen (NWC), and VAS (0-10). Higher PRI scores indicate greater pain severity.
Time frame: Pain assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
Quality of life related to menstruation: Specific quality of life questionnaire related to menstruation (CVM-22)
It assess the impact of menstruation on the woman's health status during bleeding days. The CVM-22 is a self-administered Likert-type questionnaire, made up of 22 items, where the questionnaire score ranges between 0 and 66, higher scores indicate worse quality of life.
Time frame: Assessment using the scale will be conducted on the first day of menstrual bleeding during three consecutive cycles, together with the other scales.
Ran from Feb 2024 to primary completion in Apr 2026, 25 months.
Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 25 months is above that.
Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jun 2024 → Apr 2026 and completion Jun 2024 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.